The role of apoptosis, proliferation and amifostine in the myelodysplastic syndromes (MDS) and AML secondary to MDS.

被引：0
|
作者：
Parker, JE [1 ]
Fishlock, KL [1 ]
Pagliuca, A [1 ]
Mufti, GJ [1 ]
机构：
[1] Univ London Kings Coll, Sch Med & Dent, London, England
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1729
引用
收藏
页码：418A / 419A
页数：2
相关论文
共 50 条
  • [21] Rigosertib in myelodysplastic syndromes (MDS)
    Raza, A.
    Ali, A. M.
    Reddy, M. V. R.
    Hoffman, B. S.
    Petrone, M. E.
    Maniar, M.
    Pinheiro, R. F.
    Coutinho, D. F.
    Fruchtman, S. M.
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (09): : 981 - 988
  • [22] The pathogenesis of myelodysplastic syndromes (MDS)
    Platzbecker, Uwe
    Meredyth-Stewart, Michelle
    Ehninger, Gerhard
    CANCER TREATMENT REVIEWS, 2007, 33 : S53 - S58
  • [23] Myelodysplastic syndromes (MDS) Preface
    Klimek, Virginia
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2015, 28 (01) : 1 - 2
  • [24] Treatment of myelodysplastic syndrome (MDS) with amifostine.
    deCastro, CM
    Gockerman, JP
    Moore, JO
    Hartung, C
    Misuraca, J
    BLOOD, 1998, 92 (10) : 251B - 251B
  • [25] The AML-MDS interface-leukemic transformation in myelodysplastic syndromes
    Porwit A.
    Saft L.
    Journal of Hematopathology, 2011, 4 (2) : 69 - 79
  • [26] A BMT model mice for myelodysplastic syndromes (MDS) and transformation to AML.
    Watanabe-Okochi, Naoko
    Kitaura, Jiro
    Harada, Hironori
    Ono, Ryoichi
    Nakajima, Hideaki
    Nosaka, Tetsuya
    Inaba, Toshiya
    Kitamura, Toshio
    BLOOD, 2006, 108 (11) : 744A - 744A
  • [27] Hypomethylation therapy of decitabine in patients with myelodysplastic syndromes (MDS) induces apoptosis and reduces proliferation.
    Jilani, I
    Kantarjian, H
    Gorre, M
    Issa, JP
    Bennett, J
    Raza, A
    Ravandi, F
    Saba, H
    Albitar, M
    BLOOD, 2005, 106 (11) : 112A - 112A
  • [28] Role of fludarabine containing regimens in newly-diagnosed AML or MDS.
    Estey, E
    Thall, P
    Kantarjian, H
    Pierce, S
    Freireich, E
    BLOOD, 1998, 92 (10) : 232A - 233A
  • [29] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS): Impact on hematopoiesis.
    List, AF
    Holmes, H
    Vempaty, H
    Greenberg, PL
    Bennett, JM
    BLOOD, 1998, 92 (10) : 714A - 714A
  • [30] Acquired specific granule deficiency in the myelodysplastic syndromes (MDS): A study of 191 previously untreated patients entered on CALGB protocols for MDS.
    Elghetany, MT
    MacCallum, JM
    Nelson, DA
    Varney, JF
    Sullivan, AK
    Silverman, LR
    Schiffer, CA
    Davey, FR
    Bloomfield, CD
    BLOOD, 1995, 86 (10) : 1331 - 1331
12345